glp 1 drugs and kidney function Nephroprotective effects of GLP-1 receptor agonists: where do we stand? | Journal of Nephrology Kidney Outcomes With Glucagon-Like Peptide-1

Liraglutide has also been seen to inhibit tau-hyperphosphorylation in DR, thus protecting RGCs from degeneration [91]

Clinical trials stop after a few years, and some of the currently FDA-approved drugs have only been around for a couple of years

Dual GIP and GLP-1 receptor agonist Tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes

Among these studies, three were classified as case series [3335], while the remaining were observational studies [4, 3648]

However, there are marketing strategies that can help businesses promote semaglutide to healthcare professionals and patients

For more in-depth analyses and the latest updates on diabetes management, visit our Insights section